Asset Details
Do you wish to reserve the book?
Pharmacokinetics of Antimycobacterial Drugs in Patients with Tuberculosis, AIDS, and Diarrhea
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pharmacokinetics of Antimycobacterial Drugs in Patients with Tuberculosis, AIDS, and Diarrhea
Do you wish to request the book?
Pharmacokinetics of Antimycobacterial Drugs in Patients with Tuberculosis, AIDS, and Diarrhea
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pharmacokinetics of Antimycobacterial Drugs in Patients with Tuberculosis, AIDS, and Diarrhea
1997
Overview
To test the hypothesis that antituberculous drug disposition is altered in patients with AIDS, we studied the steady-state pharmacokinetics of isoniazid (300 mg/d), rifampin (600 mg/d), and pyrazinamide (1,500 mg/d) in 29 adults (14 patients infected with human immunodeficiency virus [HIV] and 15 non-HIV-infected patients) with tuberculosis in Nairobi, Kenya. Intestinal integrity was assessed with xylose. Neither HIV infection nor diarrhea accounted for the interpatient variability in the area-under-the-plasma concentration vs. time curve (AUC), the maximum concentration, or the terminal half-life (t1/2) of isoniazid, rifampin, and pyrazinamide. No significant association between HIV infection or diarrhea and pharmacokinetics was seen for any of the compounds. In addition, neither the AUC nor the t1/2 of any of these drugs reflected interpatient differences in CD4 lymphocyte counts. Xylose absorption was uniformly low. We did not demonstrate that HIV infection, diarrhea, or CD4 lymphocyte counts contributed significantly to the variability in pharmacokinetics of isoniazid, rifampin, and pyrazinamide in TB patients in Nairobi.
Publisher
The University of Chicago Press,University of Chicago Press
Subject
/ AIDS
/ AIDS-Related Opportunistic Infections - complications
/ AIDS-Related Opportunistic Infections - metabolism
/ Antitubercular Agents - pharmacokinetics
/ Biological and medical sciences
/ Diarrhea
/ Female
/ HIV
/ Humans
/ Immunodeficiencies. Immunoglobulinopathies
/ Isoniazid - pharmacokinetics
/ Male
/ Pyrazinamide - pharmacokinetics
